Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
| Market Cap | Shares Float | Float Held by Institutions % | Shares Outstanding | Shares Authorized | Institutional Own % |
|---|---|---|---|---|---|
| 1,801.27 M | 131.08 M | 75% | 131.19 M | 278.00 M | 100.52% |
| Date of Short Interest by FINRA | Shares Sold Short | Short Float % | Insider Own % | Number Institutions Holding Shares |
|---|---|---|---|---|
| 31-Aug-2023 | 14.03 M | 11.00% | 0.23% | 303 |
| Financial Doc Link | Date of Doc | Cash Equivalents | Marketable Securities | Cash Flow Operating Activities (monthly) | Operating Expenses (monthly) |
|---|---|---|---|---|---|
| 10-Q | 02-May-2023 | $174.35 M | $477.61 M | $9.21 M | $25.72 M |
| Current Assets | Current Liabilities | Working Capital | Total Assets | Total Liabilities | Total Revenues (12 mo) |
|---|---|---|---|---|---|
| $830.14 M | Unavailable | Unavailable | $969.92 M | $406.19 M | $459.40 M |
Dilutive convertible shares can impact a stock's price by increasing the number of outstanding shares, potentially reducing the value of existing shares and decreasing the stock price.
Stock Warrants can increase share count when exercised. This dilutions affects earnings per share and potentially reduces stock value and impacting investments.
Shelf Registrations can impact a stock's price by increasing the supply of shares available for sale, potentially lowering demand and decreasing stock price, leading to decreased returns on investors.
Shelf Registrations can impact a stock's price by increasing the supply of shares available for sale, potentially lowering demand and decreasing stock price, leading to decreased returns on investors.
Sign up to see if this company has any automatic shelf registrations
Shelf Registrations can impact a stock's price by increasing the supply of shares available for sale, potentially lowering demand and decreasing stock price, leading to decreased returns on investors.
Sign up to see if this company has any shelf registrations pending effect
Registration Statements, which provide information on a company's financials and business plans before a public offering, can impact trading by affecting investor perception and demand for the stock, potentially leading to price changes.
Sign up to see if this company has any registration statements
Registration Statements, which provide information on a company's financials and business plans before a public offering, can impact trading by affecting investor perception and demand for the stock, potentially leading to price changes.
Sign up to see if this company has any registration statements pending effect
Company current reports can impact investments by providing important information on material events and changes at the company, affecting the stock price and potential for gains or losses.